| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities | |||||||||
Net loss | |||||||||
-97,634 | -90,751 | -42,809 | - | - | - | - | - | - | - |
Net loss | |||||||||
- | - | - | -44,261 | -28,453 | -23,788 | -19,403 | -24,790 | -34,344 | -15,290 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Depreciation and amortization | |||||||||
494 | 643 | 219 | - | - | - | - | - | - | - |
Stock-based payments to consultants | |||||||||
- | - | - | - | - | - | - | 339 | 3,990 | 0 |
Depreciation and amortization | |||||||||
- | - | - | 80 | 64 | 10 | 6 | 4 | 3 | 12 |
Stock-based compensation | |||||||||
20,558 | 28,485 | 8,601 | 5,024 | 7,876 | 10,637 | 1,712 | 2,831 | 2,982 | 2,356 |
Net accretion and amortization of investments in marketable securities | |||||||||
1,735 | 229 | 0 | - | - | - | - | - | - | - |
Non-cash rent expense | |||||||||
4,454 | 0 | 0 | - | - | - | - | - | - | - |
Amortization of discount on marketable securities, net | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Realized loss from marketable securities | |||||||||
- | - | - | -1,140 | -27 | 0 | - | - | - | - |
Deferred income tax benefit | |||||||||
-800 | 1,100 | -9,100 | -618 | 0 | 0 | - | - | - | - |
Loss on disposal of fixed assets | |||||||||
-102 | 0 | 0 | - | - | - | - | - | - | - |
Other | |||||||||
5 | 0 | -615 | - | - | - | - | - | - | - |
Loss on sale of fixed assets | |||||||||
- | - | - | - | -0 | 0 | - | - | - | - |
Issuance of warrants for services | |||||||||
- | - | - | - | - | 679 | 0 | - | - | - |
Amortization of deferred financing costs and debt discount | |||||||||
- | - | - | - | - | - | - | 0 | 328 | 2,327 |
Non-cash research and development | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Expenses paid on behalf of the Company satisfied through the issuance of notes | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Changes in operating assets and liabilities: | |||||||||
Accounts receivable from collaboration | |||||||||
944 | 156 | 2,273 | 0 | 0 | - | - | - | - | - |
Prepaid expenses and other current assets | |||||||||
3,685 | 1,094 | 286 | -93 | 555 | 54 | - | - | - | - |
Other assets | |||||||||
-1,664 | 3,008 | 84 | 58 | - | - | - | - | - | - |
Prepaid research and development | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Other current assets | |||||||||
- | - | - | - | - | - | 4 | -2 | 43 | 16 |
Accounts payable | |||||||||
-1,962 | 1,569 | -244 | 1,004 | 456 | -2,481 | 767 | - | - | - |
Accrued clinical expenses | |||||||||
1,265 | 3,119 | -242 | - | - | - | - | - | - | - |
Other accrued expenses | |||||||||
2,016 | 382 | 1,628 | - | - | - | - | - | - | - |
Accrued expenses | |||||||||
- | - | - | 2,714 | 1,968 | 23 | -874 | - | - | - |
Deferred revenue | |||||||||
-3,612 | -5,125 | 45,785 | - | - | - | - | - | - | - |
Deferred revenue | |||||||||
- | - | - | 0 | 0 | - | - | - | - | - |
Deferred rent | |||||||||
0 | -108 | 0 | - | - | - | - | - | - | - |
Operating lease liabilities | |||||||||
-4,269 | 0 | 0 | - | - | - | - | - | - | - |
Deferred rent | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Security deposits | |||||||||
- | - | - | - | -82 | 0 | 0 | - | - | - |
Accounts payable and accrued expenses | |||||||||
- | - | - | - | - | - | - | 232 | 2,012 | -3,049 |
Net cash used in operating activities | |||||||||
-84,067 | -64,958 | 1,860 | -34,882 | -18,697 | -14,973 | -17,796 | -21,379 | -25,068 | -5,214 |
Cash flows from investing activities | |||||||||
Purchases of property and equipment | |||||||||
1,554 | 340 | 865 | 147 | 58 | 149 | 6 | 3 | 11 | 0 |
Purchases of marketable securities | |||||||||
281,334 | 183,941 | 48,234 | - | - | - | - | - | - | - |
Proceeds from maturities of marketable securities | |||||||||
203,911 | 48,884 | 33,457 | - | - | - | - | - | - | - |
Proceeds from sale of marketable securities | |||||||||
28,659 | 0 | 0 | - | - | - | - | - | - | - |
Sale of fixed assets | |||||||||
- | - | - | - | 0 | 0 | - | - | - | - |
Cash acquired in business combination | |||||||||
- | - | - | - | - | -509 | 0 | - | - | - |
Security deposits collected | |||||||||
- | - | - | - | - | 81 | - | - | - | - |
Purchases of marketable securities | |||||||||
- | - | - | 7,951 | 69,781 | 0 | - | - | - | - |
Proceeds from maturities of marketable securities | |||||||||
- | - | - | 44,294 | 4,983 | 0 | - | - | - | - |
Net cash provided by investing activities | |||||||||
-50,318 | -135,397 | -15,642 | 36,196 | -64,855 | 277 | -6 | -3 | -11 | - |
Cash flows from financing activities | |||||||||
Proceeds from the exercise of stock options | |||||||||
- | - | - | 153 | 554 | 0 | - | - | - | - |
Proceeds from common stock and pre-funded warrants sold, net of underwriters' discount and costs | |||||||||
134,661 | 155,425 | 64,847 | - | - | - | - | - | - | - |
Proceeds from the issuance of common stock under ESPP | |||||||||
747 | 408 | 0 | 0 | - | - | - | - | - | - |
Proceeds from the exercise of stock options | |||||||||
4,238 | 3,960 | 2,393 | - | - | - | - | - | - | - |
Net proceeds from the issuance of common stock through equity plans | |||||||||
- | - | - | 0 | 81,014 | 16,725 | 24,374 | 4,166 | 49,988 | 15,184 |
Proceeds from notes payable | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Proceeds from notes payable to related parties | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 950 |
Payment for deferred financing costs | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 755 |
Repayment of notes | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Repayment of notes payable - related party | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Proceeds from private placement | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Proceeds from the exercise of warrants and options | |||||||||
- | - | - | - | - | - | - | 730 | 288 | 0 |
Proceeds from utilization of short-term note and line of credit | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 99 |
Repayment of debt facilities | |||||||||
- | - | - | - | - | - | - | 0 | 419 | 0 |
Proceeds from term note payable | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 800 |
Repayment of term note payable | |||||||||
- | - | - | - | - | - | - | 0 | 800 | 0 |
Proceeds from receipt of subscriptions | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Net cash provided by financing activities | |||||||||
139,646 | 159,793 | 67,240 | 153 | 81,569 | 16,725 | 24,374 | 4,896 | 47,485 | 19,704 |
Net decrease in cash and cash equivalents | |||||||||
5,261 | -40,562 | 53,458 | - | - | - | - | - | - | - |
Net decrease in cash and cash equivalents | |||||||||
- | - | - | 1,467 | -1,983 | 2,029 | 6,572 | -16,486 | 22,404 | 14,489 |
Shares issued for option exercise - receivable | |||||||||
- | - | - | - | - | 368 | 0 | - | - | - |
Change in unrealized (loss) gain on marketable securities available-for-sale | |||||||||
- | - | - | - | -821 | 0 | - | - | - | - |
Cashless exercise of warrants | |||||||||
- | - | - | - | 0 | 0 | - | - | - | - |
Conversion of preferred stock to common stock | |||||||||
- | - | - | - | - | 0 | 0 | - | - | - |
Supplemental non-cash investing and financing activities | |||||||||
Operating lease liabilities arising from obtaining right-of-use assets | |||||||||
15,261 | 0 | 0 | - | - | - | - | - | - | - |
Other current assets | |||||||||
- | - | - | - | - | 23 | 0 | - | - | - |
Equipment, net | |||||||||
- | - | - | - | - | 10 | 0 | - | - | - |
Intangible assets | |||||||||
- | - | - | - | - | 29,000 | 0 | - | - | - |
Goodwill | |||||||||
- | - | - | - | -99 | 12,737 | 0 | - | - | - |
Security deposits | |||||||||
- | - | - | - | - | 16 | 0 | - | - | - |
Accounts payable and accrued expenses | |||||||||
- | - | - | - | -99 | 874 | 0 | - | - | - |
Share exchange - business combination | |||||||||
- | - | - | - | - | 29,064 | 0 | - | - | - |
Fair value of vested options and restricted stock units - in connection with business combination | |||||||||
- | - | - | - | - | 758 | 0 | - | - | - |
Deferred tax liability | |||||||||
- | - | - | - | - | 11,600 | 0 | - | - | - |
Cash acquired in business combination | |||||||||
- | - | - | - | 0 | 509 | 0 | - | - | - |
Warrants issued to placement agent | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Warrants issued to investors in connection with convertible notes | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 1,166 |
Notes and accrued interest converted to common stock | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 14,003 |
Supplemental disclosure - cash paid for interest | |||||||||
- | - | - | - | - | - | - | 0 | 277 | 76 |